Previous 10 | Next 10 |
Image source: The Motley Fool. Amarin (NASDAQ: AMRN) Q3 2020 Earnings Call Nov 05, 2020 , 7:30 a.m. ET Operator Continue reading For further details see: Amarin (AMRN) Q3 2020 Earnings Call Transcript
Amarin Corporation plc (AMRN) Q3 2020 Earnings Conference Call November 5, 2020 07:30 ET Company Participants Elisabeth Schwartz - Senior Director, Investor Relations John Thero - President & Chief Executive Officer Craig Granowitz - Chief Medical Office Mike Kalb - Chief Financial Office...
Amarin (AMRN) Q3 results:Revenues: $156.5M (+39%) vs consensus of $154.6M; Product revenue: $155.2M (+38.2%).Net loss: $6.8M (-96.1%); EPS: ($0.02) (-100.0%); non-GAAP Net Income: $4.8M (-6.5%); non-GAAP EPS: $0.01 (flat Y/Y) in-line with consensus.Cash and cash equivalents: ~$...
Amarin (AMRN): Q3 Non-GAAP EPS of $0.01 in-line; GAAP EPS of -$0.02 misses by $0.03.Revenue of $156.5M beats by $1.87M.Press Release For further details see: Amarin EPS in-line, beats on revenue
Total Revenue Increased 39 % in Third Quarter 2020 and 56% in First Nine Months of 2020 Compared to Same Periods of 2019 Despite COVID-19 Headwinds Progress Continues Towards VASCEPA ® (icosapent ethyl)...
[[AAON]], [[AAWW]], [[ABC]], [[ACIW]], [[AEIS]], [[AGIO]], [[ALNY]], [[AMRN]], [[AZN]], [[BABA]], [[BCE]], [[BDX]], [[BLL]], [[BMY]], [[CAH]], [[CCOI]], [[CEVA]], [[CGEN]], [[CHH]], [[CI]], [[CNK]], [[CNP]], [[CNQ]], [[COMM]], [[CORE]], [[CPRI]], [[CRON]], [[CWEN]], [[D]], [[DISCA]], [[DNB]],...
Amarin (NASDAQ:AMRN) is scheduled to announce Q3 earnings results on Thursday, November 5th, before market open.The consensus EPS Estimate is $0.01 (flat Y/Y) and the consensus Revenue Estimate is $154.63M (+37.6% Y/Y).Over the last 2 years, AMRN has beaten EPS estimates 88% of the time and h...
Penny Stocks To Watch Before November One of the most consistently resilient industries in the stock market today is biotech. With that penny stocks have played a relatively larger role especially this year. The coronavirus has also had a hand in propelling a number of these small-c...
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that new scientific findings that add to the growing body of knowledge on VASCEPA ® (icosapent ethyl) in patients at risk for major adverse cardiovascular e...
A once high-flying drug might be poised to take to the skies again. Amarin (NASDAQ: AMRN) released clinical trial results Monday that showed its Vascepa heart medicine effectively reduced cardiovascular events in patients with decreased kidney function. The late-stage trial is a...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...